Clinical Trial

Effect of a Dairy Product for Pregnant and Lactating Women on the Composition of Human Milk

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 15, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Vulnerable populations, who have deficient diets, may produce human milk (HML) that is not adequate in all nutrients, and this will have consequences on the growth and development of the child. In 2021, at IDIP, a specific milk product for pregnant and lactating women, Super Mil Mamá ( SMM, whole milk powder fortified with multiple vitamins, minerals, and DHA ) was designed and developed as part of a key strategy to incorporate into public policies for the first 1000 days of life. However, the potential benefits of this product have not yet been evaluated at the population level. The main objective is to evaluate the effect of the consumption of a milk product (SMM) designed for pregnant women on maternal nutritional status and the composition of human milk at one month postpartum. Specific objectives include: To compare the concentrations of DHA, Vitamins A, E, and D, Iron, Iodine, Zinc, and Calcium in human milk at one month postpartum of mothers who consumed SSM or not. To compare the concentrations of DHA, Vitamins A, E, D and Zinc in blood and the nutritional status of maternal iron between mothers who consumed SSM and those who did not.
Trial Details
NCT Number NCT07173881
Lead Sponsor Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri
Collaborators: Hospital Interzonal de Agudos General San Martín
Conditions Pregnancy
Enrollment 20 participants
Start Date 2025-08-01
Primary Completion 2025-10-30 (estimated)
Study Completion 2026-01-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-15